Compare Abeona Therapeutics Inc (ABEO) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs JPMorgan Equity Premium Income ETF — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while JPMorgan Equity Premium Income ETF trades at $56.57. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | JEPI | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.23 | $59.88 |
52-Week Low | $4.17 | $55.29 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
JEPI trades at $56.75, up 0.07% on the day, with a bullish technical signal from moving averages. The ETF's covered-call strategy generates an 8%+ yield, providing income but capping upside potential. Recent news highlights its role as a low-volatility hedge amid muted S&P 500 volatility, though tax efficiency comparisons with peers like SPYI are a focus.
The outlook for JEPI centers on income generation in flat or declining markets, with risks including underperformance in strong bull runs and tax implications on distributions. Its active management offers resilience, but total return may lag the broader market over time.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
